Thrombolysis for patients > 80 – a different view Peter Sandercock On behalf of the IST3 collaborative Group UKSF Glasgow 1 st December 2009.

Slides:



Advertisements
Similar presentations
UPDATE ON THROMBOLYTIC THERAPY Markku Kaste Department of Neurology Helsinki University Central Hospital (HUCH) University of Helsinki Markku Kaste Department.
Advertisements

Breaking news from IST-3 Peter Sandercock University of Edinburgh on behalf of the IST-3 collaborative group ESC London 29 th May 2013.
TPA in Stroke: What's All the Fuss?. FERNE Brain Illness and Injury Course.
Thrombolysis for stroke in older people.
Emily O’Brien, MSPH Predoctoral Trainee February 16, 2010 The North Carolina Stroke Care Collaborative Clinical Outcomes among Stroke Patients Receiving.
Maximizing IV Thrombolytic Therapy in Acute Ischemic Stroke Kamakshi Lakshminarayan, MD PhD Assistant Professor Neurology & Epidemiology University of.
The third international stroke trial (IST-3) of thrombolysis main results III. Effect of iv thrombolysis with iv rt-PA on death or dependency in the 3035.
Anticoagulation in Acute Ischemic Stroke. TPA: Tissue Plasminogen Activator 1995: NINDS study of TPA administration Design: randomized, double blind placebo-controlled.
Brain Single-Photon Emission CT With HMPAO and Safety of Thrombolytic Therapy in Acute Ischemic Stroke Proceedings of the Meeting of the SPECT Safe Thrombolysis.
Long-term predictive value of assessment of coronary atherosclerosis by contrast- enhanced coronary computed tomography angiography: meta- analysis and.
TPA in Acute Ischemic Stroke: The NINDS Reanalysis & Meta-analysis Data Sidney Starkman, MD, FACEP.
T-PA in Treatment of Acute Stroke: What We Know From NINDS 2004 vs 2000 Sidney Starkman, MD Departments of Emergency Medicine and Neurology, UCLA UCLA.
SYDNEY MEDICAL SCHOOL What do the IST-3 results mean for the elderly patient with acute stroke? Westmead Hospital Clinical School | George Institute for.
Primary PCI Treatment of choice for Acute MI.
The third international stroke trial (IST-3) of rt-PA. Main Results II: IST3 in context of updated meta-analysis of the randomised trials. JM Wardlaw,
IST-3 – an imaging substudy Dr Ingrid Kane Clinical research fellow.
The third international stroke trial (IST-3) main results: primary and secondary outcomes among 3035 patients The IST3 collaborative group hospitals.
The need for trials of i.v. thrombolysis in acute ischaemic stroke 10 th January 2008.
Systematic Reviews.
IST-3 Collaborators meeting Barcelona, 27 th May 2010.
Maximizing IV Thrombolytic Therapy in Acute Ischemic Stroke Kamakshi Lakshminarayan, MD PhD Assistant Professor Neurology & Epidemiology University of.
Evidence based stroke medicine. Evaluating treatments for acute ischaemic stroke -what works and what doesn’t? Professor Peter Sandercock.
What’s on the horizon? Peter Sandercock ESC Lisbon 23rd May 2012.
Thrombolysis in acute ischaemic stroke – Updated Cochrane Thrombolysis metaanalysis JM Wardlaw, V Murray, PAG Sandercock University of Edinburgh and Karolinska.
Rationale: Why do we still need a large trial? IST-3 The Third International Stroke Trial: National Coordinators’ Meeting 25 May 2005, Bologna Professor.
IST3 Perfusion and Angiography Study Collaborators Meeting ESC 2010, Barcelona, May 27 th 2010.
Tissue Plasminogen Activator for Acute Ischemic Stroke National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group.
Evidence in the ED Byron Drumheller, MD Penn Emergency Medicine.
28th April 2008 What scans to perform for patients entered in IST3 and how to send them to the trial office Eleni Sakka Joanna Wardlaw Peter Sandercock.
Evidence based stroke medicine. Evaluating treatments for acute ischaemic stroke -what works and what doesn’t? Professor Peter Sandercock.
Update on IST-3 and other trials. Or, ‘how the ECASS-3 results have helped re-launch IST-3!’ Professor Peter Sandercock, Co-chief investigator IST-3 collaborator’s.
AIRE: Acute Infarction Ramipril Efficacy study Purpose To determine whether the ACE inhibitor ramipril reduces mortality in patients with evidence of heart.
S afe I mplementation of T hrombolysis in S troke Slide presentation adapted from
The third international stroke trial (IST-3) effect of thrombolysis on outcomes at 18 months in 2348 patients in long-term follow- up cohort The IST3 collaborative.
RMH Comprehensive Stroke Centre Thrombolysis and Stroke Units : The Evidence Professor Stephen Davis Royal Melbourne Hospital Comprehensive Stroke Centre.
Acute Ischemic Stroke Treatments Patrick J. Ward, PA-S.
Mr X, 79 years old Admitted on 5/5/00 to WGH stroke unit Dense (0/5) right arm and leg paresis Aphasic CT scan excluded a bleed Given trial treatment (IST-3)
Published in Circulation 2003 Rory Hachamovitch, MD, MSc; Sean W. Hayes, MD; John D. Friedman, MD; Ishac Cohen PhD; Daniel S. Berman, MD Comparison of.
ARCHIVING A COMPLEX DATASET: IST-3 A CASE STUDY by Jonathan Drever.
IST-3 collaborators meeting Professor Peter Sandercock University of Edinburgh, UK ISS conference, Capetown, October 2006.
Third International Stroke Trial (IST-3): response to ECASS-3 results Professor Peter Sandercock, University of Edinburgh Collaborators Meeting Vienna.
Consent in acute stroke trials: a view from IST3 Peter Sandercock University of Edinburgh SRN Training Day Newcastle 25 th June 2008.
Can patients be too mild, too severe or too old for thrombolysis? Professor Peter Sandercock University of Edinburgh ESC Hamburg 27 th May 2011 Disclosures.
IST-3: What are the implications for rt-PA therapy? Peter Sandercock University of Edinburgh on behalf of the IST-3 collaborative group ESC Lisbon 23rd.
What is the prognosis of mild and severe stroke? Eivind Berge Oslo University Hospital ESC, Lisbon, May 23 rd 2012.
IST-3: progress with the trial internationally and plans for the future Peter Sandercock Riunione Gruppo Italiano IST-3 Firenze 13 th February 2009.
Thrombolysis for acute ischaemic stroke Clinical
Long-term clinical outcome following emergency MR-based reperfusion therapy for acute middle cerebral artery occlusion Department of Stroke Treatment,
Thrombolysis: The Evidence Barry Moynihan Stroke Physician, St. George’s Hospital SITS/BASP Thrombolysis Nursing Training Day March 26 th 2012.
IST-3, SITS MOST ECASS-3 & DEFUSE Professor Peter Sandercock University of Edinburgh, UK ESC May 30 th 2007 Glasgow Competing interests:
Post contrast CT extravasation is associated with hematoma expansion in CTA spot negative patients A Ederies, A Demchuk, T Chia, et al Stroke 2009;40:
10-year stroke prevention after successful carotid endarterectomy for asymptomatic stenosis (ACST-1): a multicentre randomised trial 颈动脉内膜切除术无症状狭窄 多中心随机试验.
Table 1: Table 2: Non Therapeutic Angiograms in Acute Ischemic Stroke Patients Being Considered for Endovascular Treatment Does not Adversely Affect Patient.
Thrombectomy in Acute Stroke
SITS Monitoring Study SITS-MOST
Acute Stroke Therapy with IV Thrombolysis Lawrence R. Wechsler, M.D.
When Not to Intervene in Acute Stroke or
Baseline characteristics of the 3035 patients recruited in IST3
Volume 384, Issue 9958, Pages (November 2014)
Setareh Omran, MD Vascular Neurology Fellow
Volume 384, Issue 9958, Pages (November 2014)
Volume 14, Issue 5, Pages (May 2015)
Modified Rankin score 0-2
Volume 379, Issue 9834, Pages (June 2012)
Thrombolysis for acute ischemic stroke
Extended Window Thrombectomy
Volume 14, Issue 5, Pages (May 2015)
Volume 379, Issue 9834, Pages (June 2012)
Volume 12, Issue 8, Pages (August 2013)
Jennifer E. Fugate, DO, Alejandro A. Rabinstein, MD 
Presentation transcript:

Thrombolysis for patients > 80 – a different view Peter Sandercock On behalf of the IST3 collaborative Group UKSF Glasgow 1 st December 2009

Some questions 1.Why does age > 80 matter? 2.Are people >80 years getting rt-PA? 3.For people aged > 80 vs < 80 yrs -Are the benefits different? -Are the risks (intracranial haemorrhage) different? 4. Is there a role for specialist brain imaging to sort out which older patients should receive thrombolysis? 5. Do we need more trials in the over 80s?

Why does it matter? It’s a big problem Every year in the UK ~ 30,000 people aged > 80 have an acute ischaemic stroke EU approval for thrombolysis excludes > 80 year olds Ageism in rt-PA usage

Ageism: the older you are, the less likely you are to get rt-PA for stroke: Germany Förch. Stroke 2009;40: Age

Randomised trial evidence for rt- PA in the over 80’s? Wardlaw J et al, Cochrane Database Systematic Reviews randomised trials of rt-PA for stroke 3977 patients Only 42 patients aged > 80 years!

In patients aged < 80: effect on death OR 1.14 ( ) Wardlaw J, Cochrane Database Systematic Reviews 2009 Non-significant 14% increase in odds of death (95% CI, 5% reduction to 38% increase)

Non-randomised cohort studies. Outcome after iv thrombolysis for stroke > 80 versus <80 years of age: 6 cohort studies included 2,244 patients 477 aged ≥80 years Potential for bias - can’t adjust for baseline differences in those 80 years Engelter. Age and Ageing 2006; 35: 572–580

Non-randomised cohorts: Death Engelter. Age and Ageing 2006; 35: 572–580 People aged > 80 more likely to die with rt-PA

Non- randomised cohorts: good outcome in survivors (mRS 0-1) Engelter. Age and Ageing 2006; 35: 572–580 People aged > 80 less likely to survive with a good outcome after rt-PA

Summary of non-random studies Imbalances in baseline variables; hard to assess balance of risk and benefit Need reliable randomised evidence on the balance of risk and benefit For stroke patients aged ≥80 years, it is safe and reasonable to include such patients in randomised placebo- controlled trials. Engelter. Age and Ageing 2006; 35: 572–580

Third International Stroke Trial. A large randomised trial to answer the question: can a wider variety of patients be treated with iv therapy? Target: 3100 patients from ~ 100 centres in 12 Countries by mid 2011

IST-3 trial: randomisation If patient fits main eligibility/exclusion criteria, Clinician/patient/family discuss. If: Clear INDICATION FOR rt-PA  TREAT (i.e. meets terms of current licence and patient agrees) Clear CONTRAINDICATION TO rt-PA  DON’T TREAT rt-PA ‘PROMISING BUT UNPROVEN’  RANDOMISE

Randomised trials with IST-3 design (to include > 80’s) applauded … will inevitably include patients with comorbidities, but we need to embrace frailty… … must be flexible and use creative strategies to facilitate participation of older individuals in clinical trials. … endpoints that are relevant to older individuals should be assessed: … physical handicap, … quality of life.’ Lancet Neurology. Editorial 2009

Number of patients recruited per quarter year in each age and time stratum Age time(h) ECASS-3 published

Imaging for selection??? Structural –CT WM lesions, atrophy, old strokes –MR Microbleeds, white matter lesions, atrophy Angiography –CT –MR Perfusion –CT –MR No reliable RCT evidence!

Ongoing randomised trials IST-3 all ages < 6hrs. target = 3100 patients Predicted 1000 patients > 80 years To date IST-3 has recruited more than 800 patients > 80 years: –300/800 (37%) recruited hrs –640/800 (79%) recruited hrs More UK centres welcome TESPI 600 patients > 80 years < 3hrs To date recruited 36 patients

Summary: rt-PA for the over 80’s Why does it matter? In the UK 30,000 people/yr aged > 80 have an acute stroke! Are they getting rt-PA? Very few, and variably! For people aged > 80 vs < 80 yrs: Are the benefits different? Don’t know! Are the risks different? Don’t know! Specialist brain imaging to select? Don’t know! Need more RCT evidence in over 80s? YES

Main features of IST - 3 International, multi-centre, Prospective, Randomised, Open, Blinded Endpoints (PROBE) design study of i.v. rt-PA vs control. Independent. Investigator-led Primary outcome: the proportion of patients alive and independent at six months (Modified Rankin 0,1 or 2) Randomisation by telephone or internet with on- line minimisation to balance key prognostic factors. Blinded central review of all scans Recruitment ends mid 2011, results early 2012

USA: Increasing age reduces odds of treatment with rt-PA: Reduction (compared with age < 60) p Age 60-69*30%0.07 Age 70-79*30% Age 80-89*60% < Age 90 +*80% < Survey of 23,058 ischemic strokes in 137 US hospitals. Reed et al, Stroke 2001; 32: *

Neurology in the elderly: more trials urgently needed 1 the average age of participants in the NINDS trial of alteplase for acute stroke was 67 years 1 patients aged 80 years and older were specifically excluded from the post-registration studies; 1 consequently, alteplase is not licensed for use in patients older than 80 years. 1 ‘…the International Stroke Trial (IST-3), which is including substantial numbers of patients in this age-group, will definitively assess the effectiveness of alteplase for the very elderly’ 2 1. Editorial Lancet Neurology Sanossian. Lancet Neurology 2009

Patient selection from thrombolysis – does CTA, CTP, MRA or MRP add anything (or just delay the start of treatment)? DIAS 1& 2 RCTs – ‘we know the answer already’ - MR DWI PWI ‘mismatch’ must be present: trials negative EPITHET – RCT, but too small to say whether presence or absence of mismatch is helpful DEFUSE – no control group!!!! DIAS-3&4 – ‘we know the answer already’ - need to show a blocked artery to benefit EXTEND – no, you need ‘penumbral mismatch’ to select IST-3 aiming to collect pre-randomisation data on perfusion, angiography or both in patients

Stroke thrombolysis > 80 years Patients over 80 have been excluded from randomised trials and hence from the licence 2 randomised trials are recruiting patients > 80 –IST-3 will recruit > 1000 patients > 80yr (800 already) –Italian trial (TESPI) recruiting patients > 80yr < 3hrs. (36 to date)

Effect of IV rt-PA < on ‘death or dependency’: age < 80 Heterogeneity (Chi 2 p=0.007) I 2 = 62% Test for overall effect p= Wardlaw J et al, Cochrane Database Systematic Reviews

Symptomatic ICH Engelter. Age and Ageing 2006; 35: 572–580